Survey on the management of skin toxicity associated with EGFR inhibitors amongst French physicians.
Fiche publication
Date publication
avril 2013
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier
Tous les auteurs :
Peuvrel L, Bachmeyer C, Reguiai Z, Bachet JB, André T, Bensadoun RJ, Bouché O, Ychou M, Dréno B,
Lien Pubmed
Résumé
Epidermal growth factor receptor (EGFR) inhibitors are part of the therapeutic arsenal available for advanced cancer. However, they are frequently associated with cutaneous side-effects, which can hamper compliance, lead to treatment refusal and impair quality of life.
Mots clés
Dermatologic Agents, administration & dosage, France, Humans, Receptor, Epidermal Growth Factor, antagonists & inhibitors, Skin, drug effects, Surveys and Questionnaires
Référence
J Eur Acad Dermatol Venereol. 2013 Apr;27(4):419-29